StockData
Voyager Therapeutics, Inc. logo

Voyager Therapeutics, Inc. (VYGR) stock

VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3055% below fair value
$1.52−0.11 (-6.75%)

Close on Nov 17, 2026Market cap $93.66MP/E –Yield –

Voyager Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Voyager Therapeutics's price to sales ratio was 3.1× on Nov 11, 2026, against 7.2× a year earlier. Over the last 5 years it ranged from 0.7× to 8.1×, with a median of 3.6×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.1×−3.8
2025Dec 31, 20257.0×+5.1
2024Dec 31, 20241.9×−3.3
2023Jan 31, 20235.2×+1.8
2022Dec 30, 20223.3×−3.1
2021Dec 31, 20216.4×+5.1
2020Dec 31, 20201.4×−5.6
2019Dec 31, 20197.0×−18.4
2018Dec 31, 201825.4×−45.4
2017Dec 29, 201770.8×+51.6
2016Dec 30, 201619.3×–

More Voyager Therapeutics figures

See a number that looks wrong?